Fayez Sarofim & Co’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-4,710
| Closed | -$323K | – | 287 |
|
|
2024
Q2 | $323K | Sell |
4,710
-7,025
| -60% | -$469K | ﹤0.01% | 243 |
|
|
2024
Q1 | $860K | Hold |
11,735
| – | – | ﹤0.01% | 177 |
|
|
2023
Q4 | $865K | Sell |
11,735
-3,863
| -25% | -$301K | ﹤0.01% | 173 |
|
|
2023
Q3 | $1.17M | Buy |
15,598
+5,813
| +59% | +$447K | ﹤0.01% | 160 |
|
|
2023
Q2 | $754K | Sell |
9,785
-35,009
| -78% | -$2.79M | ﹤0.01% | 180 |
|
|
2023
Q1 | $3.72M | Buy |
44,794
+9
| +0% | +$745 | 0.01% | 119 |
|
|
2022
Q4 | $3.84M | Sell |
44,785
-200
| -0.4% | -$15.8K | 0.01% | 116 |
|
|
2022
Q3 | $2.77M | Sell |
44,985
-971
| -2% | -$61.2K | 0.01% | 126 |
|
|
2022
Q2 | $2.84M | Sell |
45,956
-11,931
| -21% | -$739K | 0.01% | 137 |
|
|
2022
Q1 | $3.44M | Sell |
57,887
-68,544
| -54% | -$4.38M | 0.01% | 137 |
|
|
2021
Q4 | $9.18M | Buy |
126,431
+18,211
| +17% | +$1.25M | 0.03% | 102 |
|
|
2021
Q3 | $7.56M | Sell |
108,220
-7,776
| -7% | -$546K | 0.03% | 105 |
|
|
2021
Q2 | $7.99M | Buy |
115,996
+25,866
| +29% | +$1.73M | 0.03% | 104 |
|
|
2021
Q1 | $5.83M | Sell |
90,130
-1,990
| -2% | -$128K | 0.02% | 102 |
|
|
2020
Q4 | $5.37M | Sell |
92,120
-4,287
| -4% | -$259K | 0.02% | 102 |
|
|
2020
Q3 | $6.09M | Sell |
96,407
-2,840
| -3% | -$197K | 0.03% | 96 |
|
|
2020
Q2 | $7.64M | Buy |
99,247
+20
| +0% | +$1.53K | 0.04% | 91 |
|
|
2020
Q1 | $7.42M | Hold |
99,227
| – | – | 0.05% | 88 |
|
|
2019
Q4 | $6.45M | Sell |
99,227
-4,800
| -5% | -$313K | 0.03% | 99 |
|
|
2019
Q3 | $6.59M | Sell |
104,027
-6,765
| -6% | -$442K | 0.03% | 100 |
|
|
2019
Q2 | $7.49M | Sell |
110,792
-8,220
| -7% | -$541K | 0.04% | 98 |
|
|
2019
Q1 | $7.74M | Sell |
119,012
-5,960
| -5% | -$396K | 0.04% | 99 |
|
|
2018
Q4 | $7.82M | Sell |
124,972
-640
| -0.5% | -$44.7K | 0.05% | 95 |
|
|
2018
Q3 | $9.7M | Sell |
125,612
-21,020
| -14% | -$1.59M | 0.05% | 93 |
|
|
2018
Q2 | $10.4M | Sell |
146,632
-23,820
| -14% | -$1.68M | 0.06% | 88 |
|
|
2018
Q1 | $12.9M | Sell |
170,452
-51,072
| -23% | -$4.06M | 0.07% | 83 |
|
|
2017
Q4 | $15.9M | Sell |
221,524
-28,747
| -11% | -$2.18M | 0.08% | 80 |
|
|
2017
Q3 | $20.3M | Sell |
250,271
-218,880
| -47% | -$16.7M | 0.11% | 77 |
|
|
2017
Q2 | $33.2M | Sell |
469,151
-205,480
| -30% | -$13.7M | 0.18% | 71 |
|
|
2017
Q1 | $45.8M | Sell |
674,631
-655,150
| -49% | -$46.1M | 0.25% | 68 |
|
|
2016
Q4 | $95.2M | Sell |
1,329,781
-78,186
| -6% | -$5.81M | 0.52% | 51 |
|
|
2016
Q3 | $111M | Sell |
1,407,967
-45,723
| -3% | -$3.71M | 0.61% | 47 |
|
|
2016
Q2 | $121M | Buy |
1,453,690
+24,389
| +2% | +$2.16M | 0.67% | 45 |
|
|
2016
Q1 | $132M | Buy |
1,429,301
+173,734
| +14% | +$15.7M | 0.75% | 41 |
|
|
2015
Q4 | $127M | Sell |
1,255,567
-31,624
| -2% | -$3.29M | 0.73% | 43 |
|
|
2015
Q3 | $126M | Sell |
1,287,191
-87,931
| -6% | -$9.77M | 0.73% | 43 |
|
|
2015
Q2 | $161M | Sell |
1,375,122
-37,440
| -3% | -$4.09M | 0.82% | 43 |
|
|
2015
Q1 | $139M | Sell |
1,412,562
-26,260
| -2% | -$2.67M | 0.68% | 52 |
|
|
2014
Q4 | $136M | Buy |
1,438,822
+35,415
| +3% | +$3.66M | 0.64% | 51 |
|
|
2014
Q3 | $149M | Buy |
1,403,407
+86,483
| +7% | +$8.47M | 0.7% | 49 |
|
|
2014
Q2 | $110M | Buy |
1,316,924
+218,618
| +20% | +$17M | 0.5% | 58 |
|
|
2014
Q1 | $78.4M | Buy |
+1,098,306
| New | +$86.1M | 0.37% | 62 |
|
Other funds holding GILD
Fayez Sarofim & Co's GILD Position: Q3 2024 in Review
Fayez Sarofim & Co sold out of Gilead Sciences (GILD) in Q3 2024, closing a stake of 4,710 shares — an estimated $323K sold.
Fayez Sarofim & Co first reported a position in GILD in Q1 2014 and held it in 42 quarters. The position peaked at $161M in Q2 2015. 1,719 funds tracked by Wall St. Rank hold GILD as of Q3 2024.
- Fayez Sarofim & Co reported no remaining Gilead Sciences position as of Q3 2024 after selling out during the quarter.
- Fayez Sarofim & Co sold 4,710 Gilead Sciences shares in Q3 2024, an estimated $323K.
- Fayez Sarofim & Co first reported a position in Gilead Sciences in Q1 2014 and held it in 42 quarters.
- Fayez Sarofim & Co's Gilead Sciences position peaked at $161M in Q2 2015.
- 1,719 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2024.
Based on Fayez Sarofim & Co's 13F filing for Q3 2024, filed 14 Nov 2024.